Clinical Trial Update: MG4101 for Refractory or Relapsed AML [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for MG4101 in refractory or relapsed acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• MG4101 (ex vivo expanded allogeneic NK cell therapy)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: COMPLETED